In contrast, other researches represented a direct significant correlation of CD166 expression with tumor regression and worse prognosis effects of this marker in preoperative chemoradiotherapy-treated colorectal adenocarcinoma specimens [45]. Here, ALCAM is linked to colorectal adenocarcinoma.